New NSF Resubmission Limits
NSF will return proposals without review after three resubmissions, increasing the importance of strategic proposal improvement and analysis.
On Fridays, any industry news that pertains to our services.
NSF will return proposals without review after three resubmissions, increasing the importance of strategic proposal improvement and analysis.
NSF moved major SBIR/STTR proposal instructions online, creating new compliance risks for applicants relying only on solicitation PDFs.
NSF SBIR/STTR proposals now require Letters of Support, creating new planning considerations for Phase I, Phase II, and Fast-Track applicants.
HHS will limit SBIR/STTR applicants to nine proposals annually, forcing companies to rethink submission volume and funding strategy.
Certain NIH and FDA components no longer accept clinical trials through Parent NOFOs, creating major application screening risks.
HHS Parent NOFOs now use a clinical trial optional structure, simplifying application selection while changing proposal strategy.
NIH SBIR/STTR funding is back, but applicants should pay close attention to new structures, requirements, and emerging signals.
Simpler.Grants.gov may reduce waiting time, but applicants delaying SAM.gov registration could still face devastating submission failures at deadline.
DOE’s SBIR/STTR overhaul signals a shift toward commercialization outcomes, faster pathways, and tighter alignment between innovation, labs, and market readiness.
SBIR/STTR has passed Congress and awaits signature. Use this short window to prepare strong proposals before solicitations return.